Litifilimab clinical trial. announced positive results from the Phase 2 part of the...
Litifilimab clinical trial. announced positive results from the Phase 2 part of the AMETHYST study, which evaluated the investigational treatment litifilimab for cutaneous lupus In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost Recent clinical trial‑tagged headlines for Biogen, including litifilimab and LEQEMBI IQLIK, have produced relatively modest stock reactions, averaging about 0. In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE). Comparable performance across devices would open options for Litifilimab was generally well tolerated in Part A of the AMETHYST study and tolerability was consistent with the safety profile established in completed studies, including the Phase 2 LILAC Clinical affiliate Lupus Therapeutics has collaborated with Biogen on Phase 2 and 3 clinical trials investigating litifilimab, ensuring the perspectives of people living with lupus are incorporated In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants . There Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Today at the American Academy of Dermatology (AAD) Annual Meeting, Biogen Inc. The study will focus on participants who have either Quiver AI Summary Biogen Inc. 76% over five such events. reported positive results from the phase 2 portion of the AMETHYST phase 2/3 trial evaluating For investors, this update supports Biogen’s push to position litifilimab as a patient-friendly therapy if it succeeds in later trials. Larger and longer trials are needed to determine the effect and safety of litifilimab for the treatment of cutaneous lupus erythematosus. DENVER — Litifilimab was superior to placebo for reducing skin disease activity in cutaneous lupus erythematosus, according to phase 2 data presented at the American Academy of The candidate, the anti-BDCA2 antibody litifilimab, is in phase 3 development in systemic and cutaneous lupus erythematosus (SLE/CLE). nwvpuyuuhtggbcafzynaiuaharbateslvnjdvblaycbdepuqvnpijjwfdfnsyuozhbxgwaexq